Positive results on primary and secondary endpoints, identifying dose for future development Direct and significant effect of CER-001 on endotoxin removal and consequent reduction in the inflammatory
Top line results by late fall 2022 A potentially modifying effect on the progression of the inflammatory cascade in sepsis Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX eligible
ABIONYX Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Rapid reversal of cytokine storm in septic patients Enhanced resolution of biomarkers for inflammation including leukocytosis compared to standard of care No treatment-related serious